{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"76.1","upperLimit":"85.3","value":"80.7"},{"groupId":"OG001","lowerLimit":"76.7","upperLimit":"85.7","value":"81.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"285"},{"groupId":"OG001","value":"292"}],"units":"Participants"}],"description":"The percentages of patients (with available PET scan) with no SRL and no PD will be compared between the two randomized arms to see if brentuximab vedotin in the chemotherapy backbone of doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone and cyclophosphamide (Bv-AVEPC) arm has a higher rate of early response compared to doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide (ABVE-PC) arm. Two-sample Z test of proportions at 1-sided alpha level of 0.05 will be used for these comparisons.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive doxorubicin hydrochloride IV over on days 1-2, bleomycin sulfate IV or SC on days 1 and 8, vincristine sulfate IV on days 1 and 8, etoposide IV on days 1-3, prednisone orally PO BID or methylprednisolone IV on days 1-7, and cyclophosphamide IV on days 1 and 2. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (ABVE-PC)"},{"description":"Patients receive brentuximab vedotin IV on day 1. Patients also receive doxorubicin hydrochloride, etoposide, prednisone or methylprednisolone, and cyclophosphamide as in Arm I and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"ARM II (Bv-AVEPC)"}],"paramType":"NUMBER","populationDescription":"All the eligible patients who had undergone randomization and had PET result by central review after completed cycle 2","reportingStatus":"POSTED","timeFrame":"After 42 days of chemotherapy","title":"Percentages of Patients With Early Response Defined as no Slow Responding Lesions (SRL) and no Progressive Disease (PD) at Any Disease Sites Determined by Positron Emission Tomography (PET) Per Deauville Criteria Through Central Review","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}